Immune checkpoint inhibitor-associated hepatotoxicity and ileitis: a diagnostic challenge in a patient on long-term nivolumab therapy
{{output}}
Introduction: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but may cause immune-related adverse events (irAEs). Nivolumab, an anti-PD-1 agent, is associated with hepatotoxicity and gastrointestinal toxicity. ... ...
